07 January 2008
Lifeline Scientific, a medical technology company primarily focused on commercialising its LifePortR Kidney Transporter, a product designed to address the global challenge of human donor organ shortages, today announced the successful completion of its flotation on the AIM Market of the London Stock Exchange. The Company raised a total of £5.4 million from the placing of new common shares with institutional and other investors at a price of 150p per share.
Seymour Pierce Limited acted as nominated adviser and broker to the Company. In conjunction with Seymour Pierce Limited, ProSeed Capital Holdings CVA advised the Company on the financing.
Arkios is regulated by the Financial Services Authority